Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VinoMetro phase II daily oral metronomic vinorelbine in endocrine-resistant HR-positive/HER2-negative advanced or metastatic breast cancer
2016-000284-17Phase 2Terminated
- Sponsor
- University Medical Center Mainz
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine in breast cancer, sponsored by University Medical Center Mainz. Primary endpoint: Clinical benefit rate at 24 weeks. Started Aug 2016; status: terminated.
02
Drugs
vinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-000284-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000284-17.